title: JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia.
authors.affiliation: Department of Internal Medicine V, University of Heidelberg, Heidelberg Germany. a.kraemer@dkfz-heidelberg.de
authors.forename: Alwin
authors.initials: A
authors.lastname: Krämer
authors.forename: Andreas
authors.initials: A
authors.lastname: Reiter
authors.forename: Jens
authors.initials: J
authors.lastname: Kruth
authors.forename: Philipp
authors.initials: P
authors.lastname: Erben
authors.forename: Andreas
authors.initials: A
authors.lastname: Hochhaus
authors.forename: Martin
authors.initials: M
authors.lastname: Müller
authors.forename: Nicholas C P
authors.initials: NC
authors.lastname: Cross
authors.forename: Amy V
authors.initials: AV
authors.lastname: Jones
authors.forename: Anthony D
authors.initials: AD
authors.lastname: Ho
authors.forename: Manfred
authors.initials: M
authors.lastname: Hensel
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D002869:Chromosome Aberrations; D002908:Chronic Disease; D004252:DNA Mutational Analysis; D016313:Genes, abl / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D053614:Janus Kinase 2 / Q000235:genetics*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D010879:Piperazines / Q000627:therapeutic use; D016133:Polymerase Chain Reaction; D011743:Pyrimidines / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C507924:JAK2 protein, human; D053614:Janus Kinase 2